Get the Stockscreener App
1.60
6.43%
-0.11
After Hours:
1.61
0.01
+0.63%
Ocugen Inc stock is traded at $1.60, with a volume of 10.26M.
It is down -6.43% in the last 24 hours and up +49.53% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.71
Open:
$1.71
24h Volume:
10.26M
Relative Volume:
2.42
Market Cap:
$467.69M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-5.9259
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-12.09%
1M Performance:
+49.53%
6M Performance:
+131.75%
1Y Performance:
+62.44%
1-Day Range:
$1.52
$1.72
1-Week Range:
$1.52
$1.88
52-Week Range:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.60 | 534.04M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Stock Shock: What’s Next? - StocksToTrade
Best data tools to analyze Ocugen Inc. stockQuarterly Trade Review & Community Consensus Trade Alerts - newser.com
Combining price and volume data for Ocugen Inc.Market Trend Report & Consistent Income Trade Ideas - newser.com
Will Ocugen Inc. stock maintain dividend yield2025 Winners & Losers & High Accuracy Trade Alerts - newser.com
Can Ocugen Inc. (2H51) stock sustain double digit ROE2025 Market Trends & Verified Entry Point Detection - newser.com
How Ocugen Inc. stock reacts to job market dataJuly 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com
Tools to assess Ocugen Inc.’s risk profileMarket Volume Report & Safe Entry Point Alerts - newser.com
Ocugen (NASDAQ:OCGN) Shares Down 7.4%Should You Sell? - MarketBeat
Will Ocugen Inc. stock outperform international peers2025 Key Highlights & Reliable Price Breakout Signals - newser.com
Exit strategy if you’re trapped in Ocugen Inc.July 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
What data driven models say about Ocugen Inc.’s futureWeekly Trading Summary & Community Verified Trade Signals - newser.com
How Ocugen Inc. (2H51) stock moves on employment data2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com
Ocugen Inc. stock prediction for this weekWeekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
A activityJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com
Will earnings trigger a reversal in Ocugen Inc.Market Growth Review & Free Reliable Trade Execution Plans - newser.com
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen, Inc. Hits New 52-Week High of $1.90, Marking Major Milestone - Markets Mojo
Ocugen to Highlight Gene Therapy Pipeline at Key Industry and Investor Conferences - MyChesCo
Published on: 2025-10-06 02:02:01 - newser.com
Automated trading signals detected on Ocugen Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
Analyzing recovery setups for Ocugen Inc. investorsJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Real time pattern detection on Ocugen Inc. stockFed Meeting & Smart Money Movement Alerts - newser.com
Published on: 2025-10-05 03:08:53 - newser.com
What drives Ocugen Inc 2H51 stock priceBull Market Opportunities & Explosive Growth Opportunities - earlytimes.in
Is Ocugen Inc 2H51 a good long term investmentPrice Volatility Patterns & You’ll Regret Not Buying These Early - earlytimes.in
Ocugen (NASDAQ:OCGN) Hits New 52-Week HighHere's Why - MarketBeat
Published on: 2025-10-03 06:57:10 - newser.com
Regression analysis insights on Ocugen Inc. performanceTrade Volume Report & Low Risk High Reward Ideas - newser.com
How to recover losses in Ocugen Inc. stockGap Down & Entry and Exit Point Strategies - newser.com
Published on: 2025-10-03 02:54:41 - newser.com
Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference - MSN
Ocugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness Diseases - Quiver Quantitative
Ocugen to Present at Industry and Investor Conferences in October 2025 - GlobeNewswire
Targeting 3 BLA Submissions: Ocugen Leadership to Present Gene Therapy Vision at Major Industry Events - Stock Titan
Traders Buy High Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen Inc Stock Analysis and ForecastInsider Selling Patterns & High Return Capital Gains - earlytimes.in
Ocugen Strikes $7.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):